BioCentury
ARTICLE | Clinical News

AQX-1125: Additional Phase II data

October 24, 2016 7:00 AM UTC

Additional data from the double-blind, North American Phase II LEADERSHIP 201 trial in 69 patients with moderate to severe BPS/IC pain showed that once-daily 200 mg oral AQX-1125 met the secondary end...